PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
BCBS New MexicoCommercial · Prior Auth · Prior Authorization · NM · Oncology, Genetics, Sleep Medicine +2 moreHigh impact

Prior Authorization Changes for Some Commercial and Government Program Members

Effective date
Oct 1, 2026
Identified
Oct 1, 2026

Summary

Blue Cross Blue Shield of New Mexico is restructuring prior authorization and clinical review processes across commercial and government plans, effective in two phases: October 1, 2026 (commercial medical oncology drugs) and January 1, 2027 (genetic testing, sleep services, oncology, orthotics, wound care, and DME codes). Multiple utilization management vendors (Carelon, Evicore, Alacura) will handle different service categories. Additionally, 'recommended clinical review' will be phased out entirely by end of 2027 for most commercial members.

Get alerts when payers change rules like this one

We check BCBS New Mexico and other payers every day and email you when a change matches your specialty and state.

Get BCBS New Mexico alertsPolicy Monitoring is free. No card required.

What to do

Action · 13 steps
01REQUIREMENTS: By October 1, 2026: Billing team must update prior authorization workflows to route medical oncology drug codes to Carelon for commercial members.
02Verify eligibility and prior authorization requirements through Availity Essentials before rendering services.
03By January 1, 2027: Billing team must implement the following changes in billing system and encounter forms: 1. Route genetic testing codes to Carelon (commercial) 2.
04Remove genetic testing codes previously routed to Carelon 3.
05Remove sleep services codes from prior authorization requirements 4.
06Route neurostimulator sleep codes to BCBSNM (transferred from Carelon) 5.
07Route miscellaneous codes from 'recommended clinical review' to BCBSNM for prior authorization 6.
08Route medical oncology therapy codes to Carelon (commercial) 7.
09Route provider-administered drug codes to Carelon (commercial) 8.
10For Medicare plans: Route oncology drugs, orthotics, wound care, and DME codes to BCBSNM 9.
11Update Part B Step Therapy Program as specified in preservice reviews Before rendering services on all affected codes: Check eligibility and benefits first through Availity Essentials or preferred vendor to confirm prior authorization requirements and applicable utilization management vendor.
12Consequences: Services performed without required prior authorization or that do not meet medical necessity criteria will be denied for payment, and the rendering provider may not seek reimbursement from the member.
13Claims without required prior authorization will not be paid.

Original notice

Prior Authorization Changes for Some Commercial and Government Program Members
bcbsnm.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account